Physician profile
Victor E Toro
NPI 1093789844
$10,496.77
in general payments reported to CMS, 2019-2025
39 companies · $3,009 in 2025
The $3,009 reported for 2025 was more than what 92% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $277 · 2022: $2,156 · 2023: $1,511 · 2024: $3,432 · 2025: $3,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,951.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,172.44 | 2020-2025 | Enhertu, Datroway, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $988.94 | 2022-2025 | Opdivo, Reblozyl, Abecma |
| Regeneron Healthcare Solutions, INC. | $704.16 | 2022-2025 | Libtayo |
| Genzyme Corporation | $532.34 | 2024-2025 | |
| Janssen Biotech, INC. | $519.78 | 2024-2025 | Rybrevant, Carvykti |
| Daiichi Sankyo INC. | $498.38 | 2022-2025 | Enhertu |
| Amgen INC. | $498.38 | 2023-2025 | Blincyto, Lumakras, Kyprolis |
| Glaxosmithkline, LLC. | $440.65 | 2022-2024 | Ojjaara, Zejula |
| Incyte Corporation | $355.09 | 2022-2024 | Jakafi, Monjuvi |
| Jazz Pharmaceuticals INC. | $337.68 | 2022-2025 | |
| Genentech USA, INC. | $257.42 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $248.92 | 2024-2025 | |
| Genmab U.S., INC. | $246.38 | 2024 | Epkinly |
| Gilead Sciences, INC. | $246.38 | 2023-2024 | Trodelvy |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $242.57 | 2020-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $213.49 | 2023-2025 | Lynparza, Keytruda |
| Servier Pharmaceuticals LLC | $213.24 | 2024-2025 | |
| Beigene USA, INC. | $212.78 | 2023-2024 | Brukinsa |
| Novocure INC. | $158.22 | 2023 | Optune |
| Dendreon Pharmaceuticals LLC | $149.86 | 2025 | Provenge |
| Blueprint Medicines Corporation | $127.00 | 2022 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2024 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $124.46 | 2022 | |
| Taiho Oncology, INC. | $124.46 | 2024 | |
| Mirati Therapeutics, INC. | $124.46 | 2023 | Krazati |
| Abbvie INC. | $124.46 | 2025 | |
| Kite Pharma, INC. | $124.46 | 2024 | |
| Emd Serono, INC. | $124.46 | 2024 | |
| Syndax Pharmaceuticals, INC. | $123.69 | 2025 | |
| Sobi, INC | $121.03 | 2024 | |
| Eisai INC. | $120.65 | 2022 | |
| Lilly USA, LLC | $110.73 | 2022 | |
| Rigel Pharmaceuticals, INC. | $107.95 | 2022 | |
| Karyopharm Therapeutics INC. | $102.72 | 2022 | |
| Geron Corporation | $101.87 | 2024 | Rytelo |
| Pfizer INC. | $99.98 | 2022 | |
| Adc Therapeutics America, INC. | $82.40 | 2022 | |
| Abiomed | $39.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Toro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.